Sign in
Taking people in United StatesPhase 1

Orca-T with a partly matched donor transplant in leukemia and myelodysplastic syndromes

Tests Orca-T with donor cell transplants in people with leukemia.

Key facts

Who runs it
Stanford University
Where
Palo Alto, United StatesSee the site
Trial code
Registry title
Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Status
Recruiting
Phase
Phase 1
People taking part
24 people, planned
Started
1 Dec 2025
Expected to end
Dec 2026
Type of study
Interventional
Treatments tested
  • ORCA-T
Record updated
23 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 70 with acute leukemia in remission or myelodysplastic syndromes who are having a stem cell transplant from a donor with one HLA mismatch (7/8), using Orca-T.

Age
18 to 70 years
Sex
All sexes can join.
Disease stage
Acute myeloid, lymphoid or mixed phenotype leukemia in complete remission (CR or CRi), with or without known minimal residual disease; or myelodysplastic syndrome that can be treated with donor stem cell transplant, or treatment-related MDS with under 10% blasts.
Earlier treatment
No earlier donor (allogeneic) stem cell transplant. Not currently on corticosteroids or other immune-suppressing treatment (topical steroids, or oral steroids up to 10 mg/day, are allowed).
Biomarker or test result
A related or unrelated donor who matches 7 of 8 HLA genes (one mismatch at HLA-A, -B, -C or -DRB1). The person must not have antibodies against the donor's mismatched HLA.

Main reasons for not taking part

  • Uncontrolled infection, or HIV, HTLV, hepatitis B or hepatitis C positive (some past hepatitis allowed if virus is undetectable)
  • Planned donor lymphocyte infusion or planned T cell depletion treatment
  • Another cancer diagnosed within the last 12 months (some resected skin cancers are allowed)
  • Heart attack or serious heart disease in the last 12 months, or stroke or lung clot in the last 6 months
  • Unwilling to use birth control for one year after transplant (people who can have children)

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Eligible diseases:; Acute myeloid, lymphoid or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi) as defined in Section 6.1.3; with or without the presence of known minimal residual disease, or; Myelodysplasic syndrome (MDS) myelodysplastic syndromes eligible for alloHSCT and/or treatment-related MDS <10% blasts
  • Age ≥ 18 and ≤ 70 years at the time of enrollment
  • Eligible for myeloablative alloHCT including one of two the myeloablative conditioning regimens (fractionated total body irradiation plus cyclophosphamide or busulfan, fludarabine, and thiotepa)
  • Has a related or unrelated donor available who is 7/8 match (single allele mismatched) at HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods
  • Estimated glomerular filtration rate (eGFR) ≥ 50 mL/minute or creatinine < 2 mg/dL
  • Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA)
  • Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50%
  • Total bilirubin < 2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included once hemolysis has been excluded)
  • Ability to understand and the willingness to provide written informed consent
  • Negative serum or urine beta-HCG test in females of childbearing potential (FCBP) within 3 weeks of enrollment; A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Able to give informed consent. Legal authorized representative (LAR) is permitted if subject is cognitively able to provide verbal assent
  • Karnofsky Performance Score ≥70%

Who cannot take part

  • Prior allogeneic HCT
  • Currently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed
  • Planned pharmaceutical in vivo or ex vivo T cell depletion, e.g., post-transplant cyclophosphamide (Cy), peri-transplant anti-thymocyte globulin (ATG), or alemtuzumab. For patients that have previously been exposed to a T cell-depleting agent, a 5 half-life washout of the agent must occur prior to planned Day 0 (day of infusion of Orca-T HSPC and Tregs )
  • Recipient positive anti-donor HLA antibodies against a mismatched allele in the selected donor determined by either:; Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing), or; Presence of anti-donor HLA antibody to any of the following HLA loci: HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, or -DPA1, with mean fluorescence intensity (MFI) >1000 by solid phase immunoassay
  • Uncontrolled bacterial, viral, or fungal infections (currently taking antimicrobial therapy and with progression or no clinical improvement) at time of enrollment including known, active tuberculosis infection
  • Known allergy or hypersensitivity to, or intolerance of, any investigational agent or ingredient therein, or planned GVHD prophylactic medications
  • Concurrent malignancy diagnosed within 12 months of enrollment, except non-melanoma skin cancers that have been curatively resected
  • Seropositive for HIV-1 or -2, HTLV-1 or -2, Hepatitis B sAg, and/or Hepatitis C antibody; *History of hepatitis B or hepatitis C is permitted if viral load is undetectable per quantitative PCR and/or NAT. In this case, monitoring for hepatitis B or hepatitis C by PCR at 3, 6, and 12 months is recommended
  • Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal or Streptomyces avidinii proteins
  • Any uncontrolled autoimmune disease requiring active immunosuppressive treatment
  • Females of childbearing potential (FCBP) or men who have sexual contact with FCBP unwilling to use effective forms of birth control or abstinence for one year after transplantation; (FCBP definition: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment. History of stroke or pulmonary embolism within 6 months of enrollment
  • Planned donor lymphocyte infusion (DLI)
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the recipient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

  • Stanford UniversityPalo Alto, United StatesContact: Alyssa KenegaiTaking people

About the trial

What the trial wants to find out

The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.

The group in the trial

  • ORCA-T + (tacrolimus and ruxolitinib)Treatment being tested

    Dual-agent tacrolimus starting on the day after Tcon infusion (Day +3 or Day +4) and ruxolitinib starting on the day after tacrolimus (Day +4 or Day +5).

    Treatment: ORCA-T

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Trial for Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation From an HLA-Mismatched Donor (7/8) With Orca-T
Plain-language title
Orca-T with a partly matched donor transplant in leukemia and myelodysplastic syndromesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06551584, who can take part
Record updated
23 June 2026